New Anti-Rejection drug may spare kidneys in lung transplant patients

NCT ID NCT04469842

First seen Jun 05, 2026 · Last updated Jun 06, 2026 · Updated 1 time

Summary

This study tests whether giving a long-acting version of the anti-rejection drug tacrolimus (Envarsus XR) early after a lung transplant is safe and might help protect kidney function. About 48 adult lung transplant recipients will be randomly assigned to receive either the long-acting drug or the standard immediate-release form. The goal is to see if the long-acting version can provide effective rejection prevention with fewer kidney side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT; COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.